Recurrent infections and immune evasion strategies of Staphylococcus aureus

Current Opinion in Microbiology

Volumn 15, Issue 1, 2012, Pages 92-99

  Kim, Hwan Keun ^a   Thammavongsa, Vilasack ^a   Schneewind, Olaf ^a   Missiakas, Dominique ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ADENOSINE SYNTHASE A; BACTERIAL PROTEIN; BACTERIUM ANTIBODY; BINDING PROTEIN; COMPLEMENT COMPONENT C3D; COMPLEMENT FACTOR H; CYTOKINE; FC RECEPTOR; IMMUNOGLOBULIN M; STAPHYLOCOCCAL BINDER OF IMMUNOGLOBULIN; STAPHYLOCOCCUS PROTEIN A; STAPHYLOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; B LYMPHOCYTE; BACTERIAL SKIN DISEASE; CELL SURFACE; CELLULAR IMMUNITY; HOST PATHOGEN INTERACTION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; INFECTION PREVENTION; NONHUMAN; PROTEIN BINDING; PROTEIN FUNCTION; RECURRENT INFECTION; REVIEW; SEPSIS; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ADENOSINE; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; CARRIER PROTEINS; COMPLEMENT SYSTEM PROTEINS; HUMANS; IMMUNE EVASION; IMMUNOGLOBULIN M; IMMUNOLOGIC FACTORS; MODELS, BIOLOGICAL; RECURRENCE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; SUPERANTIGENS; VIRULENCE FACTORS;

ANIMALIA; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS;

EID: 84856099935     PISSN: 13695274     EISSN: 18790364     Source Type: Journal    
DOI: 10.1016/j.mib.2011.10.012     Document Type: Review

References (88)

1. Lowy F.D. Staphylococcus aureus infections. New Engl J Med 1998, 339:520-532.
2. Peacock S.J., de Silva I., Lowy F.D. What determines nasal carriage of Staphylococcus aureus?. Trends Microbiol 2001, 9:605-610.
3. Neu H.C. The crisis in antibiotic resistance. Science 1992, 257:1064-1073.
4. Rooijakkers S.H., van Wamel W.J., Ruyken M., van Kessel K.P., van Strijp J.A. Anti-opsonic properties of staphylokinase. Microbes Infect 2005, 7:476-484.
5. Jin T., Bokarewa M., Foster T., Mitchell J., Higgins J., Tarkowski A. Staphylococcus aureus resists human defensins by production of staphylokinase, a novel bacterial evasion mechanism. J Immunol 2004, 172:1169-1176.
6. Chambers H.F. The changing epidemiology of Staphylococcus aureus?. Emerg Infect Dis 2001, 7:178-182.
7. Klevens R.M., Morrison M.A., Nadle J., Petit S., Gershman K., Ray S., Harrison L.H., Lynfield R., Dumyati G., Townes J.M., et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007, 298:1763-1771.
8. Klevens R.M., Edwards J.R., Gaynes R.P., System N.N.I.S. The impact of antimicrobial-resistant, health care-associated infections on mortality in the United States. Clin Infect Dis 2008, 47:927-930.
9. Rogers D.E., Tompsett R. The survival of staphylococci within human leukocytes. J Exp Med 1952, 95:209-230.
10. Kim H.K., Cheng A.G., Kim H.Y., Missiakas D.M., Schneewind O. Nontoxigenic protein a vaccine for methicillin-resistant Staphylococcus aureus infections in mice. J Exp Med 2010, 207:1863-1870.
11. Kennedy A.D., Otto M., Braughton K.R., Whitney A.R., Chen L., Mathema B., Mediavilla J.R., Byrne K.A., Parkins L.D., Tenover F.C., et al. Epidemic community-associated methicillin-resistant Staphylococcus aureus: recent clonal expansion and diversification. Proc Natl Acad Sci USA 2008, 105:1327-1332.
12. Hair P.S., Ward M.D., Semmes O.J., Foster T.J., Cunnion K.M. Staphylococcus aureus clumping factor A binds to complement regulator factor I and increases factor I cleavage of C3b. J Infect Dis 2008, 198:125-133.
13. Rooijakkers S.H., Wu J., Ruyken M., van Domselaar R., Planken K.L., Tzekou A., Ricklin D., Lambris J.D., Janssen B.J., van Strijp J.A., Gros P. Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor. Nat Immunol 2009, 10:721-727.
14. Chen H., Ricklin D., Hammel M., Garcia B.L., McWhorter W.J., Sfyroera G., Wu Y.Q., Tzekou A., Li S., Geisbrecht B.V., et al. Allosteric inhibition of complement function by a staphylococcal immune evasion protein. Proc Natl Acad Sci USA 2010, 107:17621-17626.
15. Postma B., Kleibeuker W., Poppelier M.J., Boonstra M., Van Kessel K.P., Van Strijp J.A., de Haas C.J. Residues 10-18 within the C5a receptor N terminus compose a binding domain for chemotaxis inhibitory protein of Staphylococcus aureus. J Biol Chem 2005, 280:2020-2027.
16. Foster T.J. Immune evasion by staphylococci. Nat Rev Microbiol 2005, 3:948-958.
17. Lambris J.D., Ricklin D., Geisbrecht B.V. Complement evasion by human pathogens. Nat Rev Microbiol 2008, 6:132-142.
18. van Wamel W.J., Rooijakkers S.H., Ruyken M., van Kessel K.P., van Strijp J.A. The innate immune modulators staphylococcal complement inhibitor and chemotaxis inhibitory protein of Staphylococcus aureus are located on beta-hemolysin-converting bacteriophages. J Bacteriol 2006, 188:1310-1315.
19. Patel D., Wines B.D., Langley R.J., Fraser J.D. Specificity of staphylococcal superantigen-like protein 10 toward the human IgG1 Fc domain. J Immunol 2010, 184:6283-6292.
20. Langley R., Patel D., Jackson N., Clow F., Fraser J.D. Staphylococcal superantigen super-domains in immune evasion. Crit Rev Immunol 2010, 30:149-165.
21. Laarman A., Milder F., van Strijp J., Rooijakkers S. Complement inhibition by Gram-positive pathogens: molecular mechanisms and therapeutic implications. J Mol Med (Berl) 2010, 88:115-120.
22. Holtfreter S., Nguyen T.T., Wertheim H., Steil L., Kusch H., Truong Q.P., Engelmann S., Hecker M., Volker U., van Belkum A., Broker B.M. Human immune proteome in experimental colonization with Staphylococcus aureus. Clin Vaccine Immunol 2009, 16:1607-1614.
23. Dryla A., Prustomersky S., Gelbmann D., Hanner M., Bettinger E., Kocsis B., Kustos T., Henics T., Meinke A., Nagy E. Comparison of antibody repertoires against Staphylococcus aureus in healthy individuals and in acutely infected patients. Clin Diagn Lab Immunol 2005, 12:387-398.
24. Jacobsson G., Colque-Navarro P., Gustafsson E., Andersson R., Mollby R. Antibody responses in patients with invasive Staphylococcus aureus infections. Eur J Clin Microbiol Infect Dis 2010, 29:715-725.
25. Bubeck Wardenburg J., Missiakas D.M., Schneewind O. Vaccines for Staphylococcus aureus infections. New Generation Vaccines 2008, Informa Health Care, Washington, D.C. M.M. Levine, J.B. Kaper, R. Rappuoli, M.F. Liu, A.L. Good (Eds.).
26. Cheng A.G., Schneewind O., Missiakas D. Nosocomial infections: Staphylococcus aureus. Vaccine Design: Innovative Approaches and Novel Strategies 2011, Caister Academic Press. R. Rappuoli, F. Bagnoli (Eds.).
27. McCormick J.K., Yarwood J.M., Schlievert P.M. Toxic shock syndrome and bacterial superantigens: an update. Annu Rev Microbiol 2001, 55:77-104.
28. Silverman G.J., Goodyear C.S. Confounding B-cell defences: lessons from a staphylococcal superantigen. Nat Rev Immunol 2006, 6:465-475.
29. Jardetzky T.S., Brown J.H., Gorga J.C., Stern L.J., Urban R.G., Chi Y.I., Stauffacher C., Strominger J.L., Wiley D.C. Three-dimensional structure of a human class II histocompatibility molecule complexed with superantigen. Nature 1994, 368:711-718.
30. Proft T., Fraser J.D. Bacterial superantigens. Clin Exp Immunol 2003, 133:299-306.
31. Llewelyn M., Cohen J. Superantigens: microbial agents that corrupt immunity. Lancet Infect Dis 2002, 2:156-162.
32. Vandenesch F., Naimi T., Enright M.C., Lina G., Nimmo G.R., Heffernan H., Liassine N., Bes M., Greenland T., Reverdy M.E., Etienne J. Community-acquired methicillin-resistant Staphylococcus aureus carrying panton-valentine leukocidin genes: worldwide emergence. Emerg Infect Dis 2003, 9:978-984.
33. Choi Y., Lafferty J.A., Clements J.R., Todd J.K., Gelfand E.W., Kappler J., Marrack P., Kotzin B.L. Selective expansion of T cells expressing V beta 2 in toxic shock syndrome. J Exp Med 1990, 172:981-984.
34. Strandberg K.L., Rotschafer J.H., Vetter S.M., Buonpane R.A., Kranz D.M., Schlievert P.M. Staphylococcal superantigens cause lethal pulmonary disease in rabbits. J Infect Dis 2010, 202:1690-1697.
35. Holtfreter S., Bauer K., Thomas D., Feig C., Lorenz V., Roschack K., Friebe E., Selleng K., Lovenich S., Greve T., et al. Egc-encoded superantigens from Staphylococcus aureus are neutralized by human sera much less efficiently than are classical staphylococcal enterotoxins or toxic shock syndrome toxin. Infect Immun 2004, 72:4061-4071.
36. Sasso E.H., Silverman G.J., Mannik M. Human IGM molecules that bind staphylococcal protein A contain VHIII H chains. J Immunol 1989, 142:2778-2783.
37. Goodyear C.S., Silverman G.J. Staphylococcal toxin induced preferential and prolonged in vivo deletion of innate-like B lymphocytes. Proc Nat Acad Sci USA 2004, 101:11392-11397.
38. Viau M., Longo N.S., Lipsky P.E., Zouali M. Staphylococcal protein A deletes B-1a and marginal zone B lymphocytes expressing human immunoglobulins: an immune evasion mechanism. J Immunol 2005, 175:7719-7727.
39. Jonsson P., Lindberg M., Haraldsson I., Wadstrom T. Virulence of Staphylococcus aureus in a mouse mastitis model: studies of alpha hemolysin, coagulase, and protein A as possible virulence determinants with protoplast fusion and gene cloning. Infect Immun 1985, 49:765-769.
40. Patel A.H., Nowlan P., Weavers E.D., Foster T. Virulence of protein A-deficient and alpha-toxin-deficient mutants of Staphylococcus aureus isolated by allele replacement. Infect Immun 1987, 55:3103-3110.
41. Cheng A.G., Kim H.K., Burts M.L., Krausz T., Schneewind O., Missiakas D.M. Genetic requirements for Staphylococcus aureus abscess formation and persistence in host tissues. FASEB J 2009, 23:3393-3404.
42. Kim H.K., Kim H.Y., Schneewind O., Missiakas D. Identifying protective antigens of Staphylococcus aureus, a pathogen that suppresses host immune responses. FASEB J 2011, 25:3605-3612.
43. Thammavongsa V., Kern J.W., Missiakas D.M., Schneewind O. Staphylococcus aureus synthesizes adenosine to escape host immune responses. J Exp Med 2009, 206:2417-2427.
44. Mazmanian S.K., Liu G., Ton-That H., Schneewind O. Staphylococcus aureus sortase, an enzyme that anchors surface proteins to the cell wall. Science 1999, 285:760-763.
45. Zimmermann H. 5'-Nucleotidase: molecular structure and functional aspects. Biochem J 1992, 285:345-365.
46. Cronstein B.N., Levin R.I., Belanoff J., Weissmann G., Hirschhorn R. Adenosine: an endogenous inhibitor of neutrophil-mediated injury to endothelial cells. J Clin Invest 1986, 78:760-770.
47. Thiel M., Caldwell C.C., Sitkovsky M.V. The critical role of adenosine A2A receptors in downregulation of inflammation and immunity in the pathogenesis of infectious diseases. Microb Infect 2003, 5:515-526.
48. Panther E., Idzko M., Herouy Y., Rheinen H., Gebicke-Haerter P.J., Mrowietz U., Dichmann S., Norgauer J. Expression and function of adenosine receptors in human dendritic cells. FASEB J 2001, 15:1963-1970.
49. Kitakaze M., Hori M., Kamada T. Role of adenosine and its interaction with alpha adrenoceptor activity in ischaemic and reperfusion injury of the myocardium. Cardiovasc Res 1993, 27:18-27.
50. Kaufmann I., Hoelzl A., Schliephake F., Hummel T., Chouker A., Lysenko L., Peter K., Thiel M. Effects of adenosine on functions of polymorphonuclear leukocytes from patients with septic shock. Shock 2007, 27:25-31.
51. Csoka B., Nemeth Z.H., Virag L., Gergely P., Leibovich S.J., Pacher P., Sun C.X., Blackburn M.R., Vizi E.S., Deitch E.A., Hasko G. A2A adenosine receptors and C/EBPbeta are crucially required for IL-10 production by macrophages exposed to Escherichia coli. Blood 2007, 110:2685-2695.
52. Voyich J.M., Braughton K.R., Sturdevant D.E., Whitney A.R., Said-Salim B., Porcella S.F., Long R.D., Dorward D.W., Gardner D.J., Kreiswirth B.N., et al. Insights into mechanisms used by Staphylococcus aureus to avoid destruction by human neutrophils. J Immunol 2005, 175:3907-3919.
53. Gresham H.D., Lowrance J.H., Caver T.E., Wilson B.S., Cheung A.L., Lindberg F.P. Survival of Staphylococcus aureus inside neutrophils contributes to infection. J Immunol 2000, 164:3713-3722.
54. Borregaard N. Neutrophils, from marrow to microbes. Immunity 2010, 33:657-670.
55. Garzoni C., Kelley W.L. Staphylococcus aureus: new evidence for intracellular persistence. Trends Microbiol 2009, 17:59-65.
56. Segal A.W. How neutrophils kill microbes. Annu Rev Immunol 2005, 23:197-223.
57. Edwards C.K., Watts L.M., Parmely M.J., Linnik M.D., Long R.E., Borcherding D.R. Effect of the carbocyclic nucleoside analogue MDL 201,112 on inhibition of interferon-gamma-induced priming of lewis (LEW/N) rat macrophages for enhanced respiratory burst and MHC class II Ia+ antigen expression. J Leukoc Biol 1994, 56:133-144.
58. Hasko G., Kuhel D.G., Chen J.F., Schwarzschild M.A., Deitch E.A., Mabley J.G., Marton A., Szabo C. Adenosine inhibits IL-12 and TNF-[alpha] production via adenosine A2A receptor-dependent and independent mechanisms. FASEB J 2000, 14:2065-2074.
59. Jensen K. A normally occuring Staphylococcus antibody in human serum. Acta Pathol Microbiol Scand 1958, 44:421-428.
60. Lindmark R., Thoren-Tolling K., Sjoquist J. Binding of immunoglobulins to protein a and immunoglobulin levels in mammalian sera. J Immunol Methods 1983, 62:1-13.
61. Forsgren A., Svedjelund A., Wigzell H. Lymphocyte stimulation by protein a of Staphylococcus aureus. Eur J Immunol 1976, 6:207-213.
62. Peterson P.K., Verhoef J., Sabath L.D., Quie P.G. Effect of protein a on staphylococcal opsonization. Infect Immun 1977, 15:760-764.
63. Sjödahl J. Repetitive sequences in protein a from Staphylococcus aureus. Arrangement of five regions within the protein, four being highly homologous and Fc-binding. Eur J Biochem 1977, 73:343-351.
64. Guss B., Uhlén M., Nilsson B., Lindberg M., Sjöquist J., Sjödahl J. Region X, the-cell-wall-attachment part of staphylococcal protein A. Eur J Biochem 1984, 138:413-420.
65. Schneewind O., Fowler A., Faull K.F. Structure of the cell wall anchor of surface proteins in Staphylococcus aureus. Science 1995, 268:103-106.
66. Graille M., Stura E.A., Corper A.L., Sutton B.J., Taussig M.J., Charbonnier J.B., Silverman G.J. Crystal structure of a Staphylococcus aureus protein a domain complexed with the fab fragment of a human igm antibody: structural basis for recognition of B-cell receptors and superantigen activity. Proc Natl Acad Sci USA 2000, 97:5399-5404.
67. Hartleib J., Kohler N., Dickinson R., Chhatwal G., Sixma J., Hartford O., Foster T.J., Peters G., Kehrl B., Herrmann M. Protein A is the von willebrand factor binding protein of Staphylococcus aureus. Blood 2000, 96:2149-2156.
68. Nguyen T., Ghebrehiwet B., Peerschke E. Staphylococcus aureus protein A recognizes platelet gC1qR/p33: a novel mechanism for staphylococcal interactions with platelets. Infect Immun 2000, 68:2061-2068.
69. Gomez M.I., Lee A., Reddy B., Muir A., Soong G., Pitt A., Cheung A., Prince A. Staphylococcus aureus protein a induces airway epithelial inflammatory responses by activating TNFR1. Nat Med 2004, 10:842-848.
70. Sullam P.M., Bayer A.S., Foss W.M., Cheung A.L. Diminished platelet binding in vitro by Staphylococcus aureus is associated with reduced virulence in a rabbit model of infective endocarditis. Infect Immun 1996, 64:4915-4921.
71. Gómez M.I., O'Seaghdha M., Prince A.S. Staphylococcus aureus protein a activates tace through EGFR-dependent signaling. EMBO J 2007, 26:701-709.
72. Martin F.J., Gomez M.I., Wetzel D.M., Memmi G., O'Seaghdha M., Soong G., Schindler C., Prince A. Staphylococcus aureus activates type I IFN signaling in mice and humans through the Xr repeated sequences of protein A. J Clin Invest 2009, 119:1931-1939.
73. Smith E.J., Visai L., Kerrigan S.W., Speziale P., Foster T.J. The Sbi protein is a multifunctional immune evasion factor of Staphylococcus aureus. Infect Immun 2011, 79:3801-3809.
74. Zhang L., Jacobsson K., Vasi J., Lindberg M., Frykberg L. A second IgG-binding protein in Staphylococcus aureus. Microbiology 1998, 144(Pt 4):985-991.
75. Atkins K.L., Burman J.D., Chamberlain E.S., Cooper J.E., Poutrel B., Bagby S., Jenkins A.T., Feil E.J., van den Elsen J.M. S. aureus IgG-binding proteins spa and sbi: host specificity and mechanisms of immune complex formation. Mol Immunol 2008, 45:1600-1611.
76. Haupt K., Reuter M., van den Elsen J., Burman J., Halbich S., Richter J., Skerka C., Zipfel P.F. The Staphylococcus aureus protein Sbi acts as a complement inhibitor and forms a tripartite complex with host complement factor H and C3b. PLoS Pathog 2008, 4:e1000250.
77. Toapanta F.R., Ross T.M. Complement-mediated activation of the adaptive immune responses: role of C3d in linking the innate and adaptive immunity. Immunol Res 2006, 36:197-210.
78. Isenman D.E., Leung E., Mackay J.D., Bagby S., van den Elsen J.M. Mutational analyses reveal that the staphylococcal immune evasion molecule sbi and complement receptor 2 (CR2) share overlapping contact residues on C3d: implications for the controversy regarding the CR2/C3d cocrystal structure. J Immunol 2010, 184:1946-1955.
79. Deisenhofer J. Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-a resolution. Biochemistry 1981, 20:2361-2370.
80. Gouda H., Shiraishi M., Takahashi H., Kato K., Torigoe H., Arata Y., Shimada I. NMR study of the interaction between the B domain of staphylococcal protein a and the Fc portion of immunoglobulin G. Biochemistry 1998, 37:129-136.
81. Projan S.J., Nesin M., Dunman P.M. Staphylococcal vaccines and immunotherapy: to dream the impossible dream?. Curr Opin Pharmacol 2006, 6:473-479.
82. Kuklin N.A., Clark D.J., Secore S., Cook J., Cope L.D., McNeely T., Noble L., Brown M.J., Zorman J.K., Wang X.M., et al. A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis model. Infect Immun 2006, 74:2215-2223.
83. Fattom A.I., Horwith G., Fuller S., Propst M., Naso R. Development of staphvax, a polysaccharide conjugate vaccine against S. aureus infection: from the lab bench to phase III clinical trials. Vaccine 2004, 22:880-887.
84. Maira-Litran T., Kropec A., Goldmann D., Pier G.B. Biologic properties and vaccine potential of the staphylococcal poly-n-acetylglucosamine surface polysaccharide. Vaccine 2004, 22:872-879.
85. Stranger-Jones Y.K., Bae T., Schneewind O. Vaccine assembly from surface proteins of Staphylococcus aureus. Proc Natl Acad Sci USA 2006, 103:16942-16947.
86. Bubeck Wardenburg J., Schneewind O. Vaccine protection against Staphylococcus aureus pneumonia. J Exp Med 2008, 205:287-294.
87. Shinefield H., Black S., Fattom A., Horwith G., Rasgon S., Ordonez J., Yeoh H., Law D., Robbins J.B., Schneerson R., et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med 2002, 346:491-496.
88. DeJonge M., Burchfield D., Bloom B., Duenas M., Walker W., Polak M., Jung E., Millard D., Schelonka R., Eyal F., et al. Clinical trial of safety and efficacy of INH-A21 for the prevention of nosocomial staphylococcal bloodstream infection in premature infants. J Pediatr 2007, 151:260-265. 265 e261.